Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
13th Nov 2006, 20:53 GMT
SEATTLE, WA and WASHINGTON, DC (MARKET WIRE) Targeted Genetics Corporation (NASDAQ: TGEN) announced that the principal investigator for its current clinical studies, Philip J. Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, will present additional interim data today from the ongoing Phase I/II trial of tgAAC94 in patients with inflammatory
Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting related news:
- Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting — Partnerships/ Joint Ventures News from StratCenter.com
- Impact Of Rheumatoid Arthritis Goes Beyond Signs And Symptoms, Delay In Treatment May Impact Long-Term Employment — Health News from Medical News Today
- ORENCIA Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria — StratWire - Business of Healthcare NewsFeed
- Early Aggressive Treatment May Alter Course Of Rheumatoid Arthritis — Health News from Medical News Today
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data — EurekAlert! - Medicine and Health
- Long-Term Data Shows No Increase In Cancer Cases From Biologic Therapy — Health News from Medical News Today
- Repeat Treatment With MabThera Provides Continuous Improvement Of Quality Of Life In Rheumatoid Arthritis Patients — Health News from Medical News Today
- Adalimumab Proves Effective For Children With Juvenile Rheumatoid Arthritis — Health News from Medical News Today
- Window Of Opportunity: Early Doses Of Methotrexate May Stop Certain Forms Of Arthritis Before They Start — Health News from Medical News Today
- Actemra™ Has A Major Impact On Improving Remission Rates In Rheumatoid Arthritis - 3 Studies From The Japanese Phase III Trial Programme — Health News from Medical News Today
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech
- GelStat Corporation: GelStat Announces the Retention of Accomplished Business Development and Marketing Firm U.S. Marketing